Meridian Bioscience — Q2 FY2022 Earnings Presentation
13 slides from Meridian Bioscience's earnings presentation, May 6, 2022
Slide 1: FY2022 Q2 Results
FY2022 Q2 Results May 6, 2022 Exhibit 99.2
Slide 2: Forward-looking statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A
Slide 3: Non-GAAP Financial Measures
Certain financial measures presented in this presentation, such as operating expenses, operating income, operating margin, net earnings and net earnings per diluted share, each on an adjusted basis, excluding as applicable the effects of changes in fair value of acquisition consideration and selecte
Slide 4: Q2 FY2022 Business Highlights
Record quarterly revenues for Company and both business segments Launched Lyo-Ready™ sample specific master mixes for blood Resumed shipment of LeadCare® II assay ahead of schedule Seamless transition of Board Chairman and addition of new CFO Q2 FY2022 Business Highlights Diagnostics Life Science
Slide 5: FY2022 Second Quarter Earnings Summary
FY2022 Second Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2022 FY2021 Change Net revenues $111,231 $85,264 +30% Gross margin % 62% 68% -6 pts Operating expenses(1) Ratio $31,760 29% $25,530 30% +24% -1 pts Operating income Margin % $36,717 33% $32,242 38% +14% -5
Slide 6: FY2022 Second Quarter Operating Segment Highlights
FY2022 Second Quarter Operating Segment Highlights ($000’s) Diagnostics segment (Adjusted Non-GAAP) FY2022 FY2021 Change Net revenues $41,103 $31,949 +29% Operating income (loss) Margin % $1,589 4% ($348) NMF NMF NMF Diagnostics segment net revenues by: Technology: Molecular assays $4,385 $4,395 --%
Slide 7: FY2022 Fiscal Year Guidance
FY2022 Fiscal Year Guidance Meridian Bioscience Diagnostics Life Science Prior Guidance (2/4/2022) Updated FY2022 Guidance Meridian Bioscience Consolidated net revenues: $330 to $345 Million Adjusted operating margin: 22.5% to 23.5% Adjusted net earnings per share*: $1.30 to $1.40 Diagnostics Net re
Slide 8: Diagnostics R&D Pipeline (as of 3/31/2022)
Diagnostics R&D Pipeline (as of 3/31/2022) Breath Immunoassay Molecular Blood Chemistry Feasibility Development Clinicals FDA Liver MBT PMA Add’l Claim (1) C. difficile Shiga Toxin Streptococcus pneumoniae / Legionella RI Panel GI Panel COVID-19 EUA(3) PediaStat Analyzer Lead Expected FY22 FDA Submi
Slide 9: Meridian ESG Efforts Encompass Four Key Areas
Meridian ESG Efforts Encompass Four Key Areas Advancing Diagnostics to Enable Better Patient Healthcare Outcomes Accelerate diagnostic test development with high-quality Life Science reagents that power hundreds of diagnostic assays across 150+ disease states Supply hospitals, outpatient clinics, re
Slide 10: Life Science Molecular Master Mixes
Life Science Molecular Master Mixes
Slide 11: Disrupting Molecular Diagnostics Development
Disrupting Molecular Diagnostics Development Meridian’s innovative sample-specific mixes (qPCR & LAMP) FAST TRACK YOUR R&D BLOOD URINE STOOL SALIVA PLANT/FOOD DNA RNA LIQUID LYOPHILIZED AIR-DRIED SPECIMEN? DETECTING? KIT FORMAT? ONLY ADD Primers & Probes INHIBITOR TOLERANT Master Mixes have everythi
Slide 12: Sample-Specific Mix Customer Trends YTD
Sample-Specific Mix Customer Trends YTD
Slide 13: Contact: mbi@meridianbioscience.com
Contact: mbi@meridianbioscience.com
Meridian Bioscience — Q2 FY2022 Earnings Presentation on 6ix